PHI with Hanot's cirrhosis (Primary Biliary Cholangitis)
How does this condition affect your private health insurance?
Hanot-Leberzirrhose, now commonly known as Primary Biliary Cholangitis (PBC), is a chronic autoimmune disease characterized by the progressive destruction of small bile ducts within the liver. This destruction leads to cholestasis, where bile acids accumulate, causing inflammation and scarring (cirrhosis) over time. Symptoms often include fatigue, pruritus (itching), and jaundice, but many individuals are asymptomatic for years. If untreated, PBC can lead to severe liver damage, liver failure, and necessitate a liver transplant. It predominantly affects women and is believed to result from a combination of genetic predisposition and environmental triggers.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Insidious onset, often several months to years before symptomatic diagnosis.
Duration of Illness (Lifetime)
Chronic, lifelong progressive disease.
Cost of Treatment (Initial)
Moderate to high (diagnostic tests, initial medication like ursodeoxycholic acid).
Cost of Treatment (Lifetime)
Very high (lifelong medication, monitoring, management of complications, potential liver transplant).
Mortality Rate
Significant without treatment; reduced with management but possible due to liver failure or complications.
Risk of Secondary Damages
High (e.g., osteoporosis, malabsorption, portal hypertension, variceal bleeding, liver cancer, severe fatigue, pruritus).
Probability of Full Recovery
Very low; it is a chronic, progressive disease with no cure, but treatment can slow progression.
Underlying Disease Risk
Moderate to high (e.g., Sjögren's syndrome, autoimmune thyroid disease, rheumatoid arthritis, scleroderma).